Cliff Asness's ADPT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 468,440 shares of Adaptive Biotechnologies Corporation (ADPT) worth $7.61 M, representing 0.00% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in ADPT, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 176,598 shares. Largest reduction occurred in Q4 2025, reducing 140,561 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Adaptive Biotechnologies Corporation (ADPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Adaptive Biotechnologies Corporation (ADPT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -140,561 | Reduce 23.08% | 468,440 | $16.24 |
| Q3 2025 | +176,598 | Add 40.84% | 609,001 | $14.96 |
| Q2 2025 | +122,131 | Add 39.36% | 432,403 | $11.65 |
| Q1 2025 | +97,444 | Add 45.79% | 310,272 | $7.30 |
| Q4 2024 | -49,136 | Reduce 18.76% | 212,828 | $5.99 |
| Q3 2024 | +79,888 | Add 43.88% | 261,964 | $5.12 |
| Q2 2024 | +129,201 | Add 244.35% | 182,076 | $3.49 |
| Q1 2024 | +13,350 | Add 33.78% | 52,875 | $3.18 |
| Q4 2023 | +26,313 | Add 199.16% | 39,525 | $4.90 |
| Q3 2023 | -12,449 | Reduce 48.51% | 13,212 | $5.45 |
| Q2 2023 | -15,962 | Reduce 38.35% | 25,661 | $6.71 |
| Q1 2023 | -28,794 | Reduce 40.89% | 41,623 | $8.66 |
| Q4 2022 | +30,856 | Add 78.00% | 70,417 | $7.45 |
| Q3 2022 | -48,309 | Reduce 54.98% | 39,561 | $7.13 |
| Q2 2022 | -75,420 | Reduce 46.19% | 87,870 | $7.83 |
| Q1 2022 | +163,290 | New Buy | 163,290 | $13.88 |
| Q2 2021 | -18,721 | Sold Out | 0 | $0.00 |
| Q1 2021 | +18,721 | New Buy | 18,721 | $39.21 |
Cliff Asness's Adaptive Biotechnologies Corporation Investment FAQs
Cliff Asness first purchased Adaptive Biotechnologies Corporation (ADPT) in Q1 2021, acquiring 18,721 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Adaptive Biotechnologies Corporation (ADPT) for 18 quarters since Q1 2021.
Cliff Asness's largest addition to Adaptive Biotechnologies Corporation (ADPT) was in Q3 2025, adding 609,001 shares worth $9.11 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 468,440 shares of Adaptive Biotechnologies Corporation (ADPT), valued at approximately $7.61 M.
As of the Q4 2025 filing, Adaptive Biotechnologies Corporation (ADPT) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Adaptive Biotechnologies Corporation (ADPT) was 609,001 shares, as reported at the end of Q3 2025.